Literature DB >> 27297962

Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.

H A Hassing1,2, M S Engelstoft2,3, R M Sichlau2,3, A N Madsen2, J F Rehfeld4, J Pedersen5, R M Jones6, J J Holst5,7, T W Schwartz2,3, M M Rosenkilde2, H S Hansen1.   

Abstract

The intestinal G protein-coupled receptor GPR119 is a novel metabolic target involving glucagon-like peptide-1 (GLP-1)-derived insulin-regulated glucose homeostasis. Endogenous and diet-derived lipids, including N-acylethanolamines and 2-monoacylglycerols (2-MAG) activate GPR119. The purpose of this work is to evaluate whether 2-oleoyl glycerol (2-OG) improves glucose tolerance through GPR119, using wild type (WT) and GPR 119 knock out (KO) mice. We here show that GPR119 is essential for 2-OG-mediated release of GLP-1 and CCK from GLUTag cells, since a GPR119 specific antagonist completely abolished the hormone release. Similarly, in isolated primary colonic crypt cultures from WT mice, GPR119 was required for 2-OG-stimulated GLP-1 release while there was no response in crypts from KO mice. In vivo, gavage with 2-oleyl glyceryl ether ((2-OG ether), a stable 2-OG analog with a potency of 5.3 µM for GPR119 with respect to cAMP formation as compared to 2.3 µM for 2-OG), significantly (P < 0.05) improved glucose clearance in WT littermates, but not in GPR119 KO mice. Finally, deletion of GPR119 in mice resulted in lower glucagon levels, whereas the levels of insulin and GIP were unchanged. In the present study we show that 2-OG stimulates GLP-1 secretion through GPR119 activation in vitro, and that fat-derived 2-MAGs are potent candidates for mediating fat-induced GLP-1 release through GPR119 in vivo.
© 2016 BioFactors, 42(6):665-673, 2016. © 2016 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  2-oleoyl glycerol; 2-oleyl glyceryl ether; GLP-1; GPR119; GPR119 knock out mice; glucagon; glucose homeostasis

Mesh:

Substances:

Year:  2016        PMID: 27297962     DOI: 10.1002/biof.1303

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  9 in total

1.  Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Authors:  Johanne A Windeløv; Nicolai J Wewer Albrechtsen; Rune E Kuhre; Sara L Jepsen; Daniel Hornburg; Jens Pedersen; Elisa P Jensen; Katrine D Galsgaard; Marie Winther-Sørensen; Anne Ørgaard; Carolyn F Deacon; Matthias Mann; Hannelouise Kissow; Bolette Hartmann; Jens J Holst
Journal:  Diabetologia       Date:  2017-07-01       Impact factor: 10.122

Review 2.  Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.

Authors:  Julien Ghislain; Vincent Poitout
Journal:  Nat Rev Endocrinol       Date:  2021-01-25       Impact factor: 43.330

Review 3.  Non-endocannabinoid N-acylethanolamines and 2-monoacylglycerols in the intestine.

Authors:  Harald S Hansen; Vasiliki Vana
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

4.  Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.

Authors:  Vincent N Marty; Mehdi Farokhnia; Joseph J Munier; Yatendra Mulpuri; Lorenzo Leggio; Igor Spigelman
Journal:  Front Neurosci       Date:  2020-12-23       Impact factor: 4.677

Review 5.  Gut microbiota: sculptors of the intestinal stem cell niche in health and inflammatory bowel disease.

Authors:  Manasvini Markandey; Aditya Bajaj; Nicholas Edward Ilott; Saurabh Kedia; Simon Travis; Fiona Powrie; Vineet Ahuja
Journal:  Gut Microbes       Date:  2021 Jan-Dec

Review 6.  Role of the gut-brain axis in energy and glucose metabolism.

Authors:  Hallie R Wachsmuth; Savanna N Weninger; Frank A Duca
Journal:  Exp Mol Med       Date:  2022-04-26       Impact factor: 12.153

Review 7.  Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.

Authors:  Jianan Zhao; Yu Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-07-07       Impact factor: 5.787

8.  Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa.

Authors:  Iain R Tough; Sarah Forbes; Herbert Herzog; Robert M Jones; Thue W Schwartz; Helen M Cox
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

9.  Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob/ob mice fed on a high-fat diet.

Authors:  Taisuke Mochida; Kazumi Take; Toshiyuki Maki; Masanori Nakakariya; Ryutaro Adachi; Kenjiro Sato; Tomoyuki Kitazaki; Shiro Takekawa
Journal:  FEBS Open Bio       Date:  2020-02-05       Impact factor: 2.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.